Asgard Therapeutics

📍 Lund, Sweden🗓 Founded 2018👥 19 employees💰 Last funded Nov 2021
Biotechnology Research🌐 asgardthx.com
Website LinkedIn
Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Asgard Therapeutics?
Asgard Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Asgard Therapeutics last raise funding?
The most recent investment in Asgard Therapeutics recorded on gritt.io was in November 2021.
When was Asgard Therapeutics founded?
Asgard Therapeutics was founded in 2018.
What industry is Asgard Therapeutics in?
Asgard Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Asgard Therapeutics based?
Asgard Therapeutics is headquartered in Lund, Sweden.